Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Cancer"
DOI: 10.1038/s41416-021-01351-8
Abstract: Background The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number read more here.
Keywords: her2 cep17; copy number; ratio her2; group ... See more keywords